Rediscovery of the Prodrug Strategy: From Small Molecules to PROTAC Innovation

Rediscovery of the Prodrug Strategy: Prodrugs are chemically modified therapeutics designed to improve drug properties such as solubility, bioavailability, and tissue selectivity. Traditionally applied to small molecules, the prodrug approach is now being extended to complex modalities like PROTACs, addressing their poor permeability and pharmacokinetics. This review outlines key prodrug strategies—enzyme activation, self-immolative linkers, redox/pH sensitivity—and highlights their roles in improving delivery and reducing toxicity. Special attention is given to “masked PROTACs,” which utilize cleavable moieties for controlled intracellular activation. Practical design considerations and evaluation methods are also discussed.

What Is a Prodrug?

A prodrug is a drug design strategy that involves chemically modifying an active pharmaceutical ingredient (API) to improve its physicochemical properties or pharmacokinetics. The prodrug itself is inactive or less active and undergoes enzymatic or chemical transformation in the body to release the active parent drug. This approach addresses various drug development challenges such as poor solubility, low stability, insufficient bioavailability, off-target toxicity, and poor membrane permeability.

01 — Approved and Commonly Used Prodrugs

Enhancing Oral Absorption & Permeability

Esterification:

Enalapril → Enalaprilat, Irinotecan → SN-38, Valacyclovir (L-valine ester of Acyclovir), Valganciclovir (L-valine ester of Ganciclovir), Dabigatran etexilate.

Phosphate/Phosphonate Esters:

Oseltamivir phosphate, Etoposide phosphate, Fosphenytoin, Fosamprenavir.

Amino Acid/Dipeptide Conjugates:

Lisdexamfetamine (lysine prodrug for abuse deterrence and extended release).

Nucleoside/Nucleotide Delivery (ProTide Strategy)

Phosphoramidate (ProTide) Prodrugs:

Sofosbuvir, Remdesivir, Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF).

Blood–Brain Barrier (BBB) Penetration

Selective in vivo release of active metabolite:

Capecitabine → 5-FU, Clopidogrel/Prasugrel (CYP activation), Prednisone → Prednisolone, Sulfasalazine (colonic bacterial cleavage).

Neuroactive agents:

Levodopa (co-transported into the brain → dopamine), Codeine (partially a prodrug of morphine).

Roughly 10–15% of approved small-molecule drugs use a prodrug strategy in some form.

02 — How to Design a Prodrug (General Workflow)

Identify the Primary Limitation:

Poor permeability/absorption

High first-pass metabolism

Low solubility

Poor selectivity

Systemic toxicity

Targeted delivery required

Choose an Activation Mechanism (Trigger):

Enzymatic Activation:

Carboxyl esterases, carbonate/carbamate cleavage, dipeptides (e.g., Val-Cit for Cathepsin B), β-glucuronidase, alkaline phosphatase.

Chemical Activation:

pH-sensitive (acetal/hydrazone), redox-sensitive (disulfide, ROS-sensitive boronate), oxidative cleavage, photolysis (o-nitrobenzyl), self-immolative spacers (PABA, trimethyl-lock).

Tissue-Selective Activation:

Microbiota (azo bonds in colon), tumor microenvironment (hypoxia, ROS, low pH).

Choose the Promoiety:

Improve Solubility:

Phosphorylation, ionizable groups (quaternary ammonium).

Enhance Permeability:

Esterification, amino acid/dipeptide conjugation, lipid chains.

Targeting/Prolonged Circulation:

Glycosylation (GLUT, ASGPR), folate receptors, albumin binders (maleimide, fatty acids).

“Stability–Release” Balance:

Must be stable in plasma/GI tract yet release the active form at a rate matching the desired exposure profile.

In Vitro–In Vivo Correlation (IVIVC):

Account for species differences (e.g., esterase expression in human vs. rodent).

Build and calibrate PBPK and release models early.

Analytical and Biomarker Considerations:

Quantify parent drug/prodrug/promoiety metabolites.

Use mass spectrometry imaging, target occupancy, or pharmacodynamic biomarkers to confirm in vivo activation.

03 — Quick Reference: Common Prodrug Strategies

Functional Group Masking:

Carboxylic acid → ester, methyl/benzyl ether

Phenols → carbonates, phosphates

Amines → amides, carbamates

Phosphate/phosphonate → SATE, ProTide

Cleavable Linkers:

PABA (self-immolative), 1,6-elimination, Val-Cit, GFLG, disulfide, hydrazone (pH 5–6), o-nitrobenzyl (light), boronate (ROS)

Targeting and Gating:

Glycosylation (liver ASGPR, tumor glucose uptake), folate conjugation, RGD motifs

Macromolecular/polymer prodrugs (PEG, HA)

Environmental Response:

pH, enzymatic, ROS, reduction (GSH-rich cytosol/tumor), hypoxia, microbiota

04 — Key Takeaways for Small-Molecule Prodrug Applications

Improving Oral Bioavailability: Most common use (esters, amino acid esters, ProTide).

Unlocking Solubility: Phosphate prodrugs enable water-soluble injectable forms (e.g., etoposide phosphate).

Tissue/Cell Selectivity: Microbiota-cleaved, tumor enzyme/ROS/pH-triggered delivery to minimize systemic toxicity.

Controlled Release/Flattening Peaks: E.g., lisdexamfetamine reduces abuse potential and side effects.